1.5 Abstract in rivista

1.5 Abstract in rivista: [1775] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 141 a 160 di 1.775

MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Metastatic Melanoma: Final Results of a Randomized Open-label Phase II Study of the EORTC Melanoma Group (16032-18031)

2009-01-01 Dreno, B; Mortier, L; Robert, C; Chiarion Sileni, V; Testorill, A; Maio, M; Awada, A; Lehmann, F; Kruit, W

Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients

2009-01-01 DI GIACOMO, ANNA MARIA; Danielli, R; Calabro, L; Bertocci, E; Nannicini, C; Miracco, C; Biagioli, M; Mazzei, Ma; Altomonte, M; Maio, M

P7 Treatment with lpllimumab brings an advantage with reference to long-term survival: reflection rate after 24-months of patients with advanced melanoma from 3 phase II studies with 10mg/kg lpillimumab

2009-01-01 O'Day, Sj; Schadendorf, D; Weber, J; Lebbe, C; Maio, M; Pehamberger, H; Harmankaya, K; Siegel, J; Hoos, A; Humphrey, R; Wolchok, J

P10 lpillimumab in a dose of 10mg/kg improves in patients sith melanoma in stage M1c the disease progression independent of lactat-dehydrogenase (LDH) level

2009-01-01 Smylie, M; Kaehler, Kc; Francis, S; Nyens, B; Maio, M; Minor, D; Verschraegen, C; Chin, K; Ibrahim, R; Hoos, A; Schadendorf, D

Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials

2009-01-01 Maio, M; Lebbe, C; Sileni Chiarion, V; Siegel, J; Hoos, A; Humphrey, R; O'Day, S; Wolchok, J; Weber, J; Harmankaya, K

Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors

2009-01-01 Schadendorf, D; Wolchok, J; Neyns, B; Lebbe, C; Harmankaya, K; Verschraegen, C; Chin, K; de Pril, V; Hoos, A; Maio, M

Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma

2010-01-01 Wolchok, Jd; Weber, Js; Hamid, O; Lebbe, C; Maio, M; Schadendorf, D; de Pril, V; Ibrahim, R; Hoos, A; O'Day, Sj

Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide

2010-01-01 Coral, S; Sigalotti, L; Parisi, G; Colizzi, F; Fratta, E; Nicolay, Hjm; Taverna, P; Maio, M

Health-Care resource Utilization in advanced melanoma: an analysis from the MELODY observational study

2010-01-01 Lorigan, P; Maio, M; Middleton, M; Testori, A; Bedane, C; van Baardewijk, M; Konto, C; Dueymes, A; Lebbe, C

Immunobiologic Activity of the Demethylating Dinucleotide SGI-110

2010-01-01 Coral, S; Sigalotti, L; Fonsatti, E; Parisi, G; Colizzi, F; Nicolay, Hj; Taverna, P; Maio, M

Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients

2010-01-01 Danielli, R; Queirolo, P; Testori, A; Plummer, R; Sileni Chiarion, V; Altomonte, M; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M

Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients

2011-01-01 Weide, B; Zelba, H; Derhovanessian, E; Pflugfelder, A; Schadendorf, D; de Vries, J; Maio, M; Garbe, C; Pawelec, G

A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial

2011-01-01 DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pittiglio, E; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Parmiani, G; Maio, M

Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma

2011-01-01 Robert, C; Thomas, L; Garbe, C; Lebbe, C; Baurain, Jf; Testori, A; Maio, M; Chen, T; Hoos, A; Wolchok, J

Estratto della tesi di dottorato: “Il principio del vivente nelle anonime Questiones super librum de anima (ms. Siena, Bibl. Com. degli Intronati L.III.21, ff. 136ra-174ra”,

2005-01-01 Bernardini, Paola

Guest Editorial “Secure lightweight crypto-hardware”

2017-01-01 Acosta, A.; Addabbo, T.

Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy

2019-01-01 Bargagli, E; Bergantini, L; Cameli, P; D'Alessandro, M; Bini, L; Rottoli, P; Landi, C

Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: experience from Italian clinics participating in the European expanded access programme (EAP)

2012-01-01 Maio, M; Chiarion Sileni, V; Pilla, L; Nicoletti, Svl; Di Guardo, L; Queirolo, P; De Galitiis, F; Mandala, M; Guida, M; Ascierto, Pa

The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases

2012-01-01 Maio, M; Testori, A; Ascierto, Pa; Ridolfi, R; Santinami, M; Pilla, L; Queirolo, P; Grosso, M; Simeone, E; Vittoria, S; Nicoletti, L; Rivoltini, L; Ferrucci, Pf; Parmiani, G; DI GIACOMO, ANNA MARIA

Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma

2012-01-01 Sigalotti, L; Fratta, E; Parisi, G; Covre, A; Sonego, P; Rizzo, A; Colizzi, F; Coral, S; Massarut, S; Maio, M

Titolo	Data di pubblicazione	Autore(i)	Abstract
MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Metastatic Melanoma: Final Results of a Randomized Open-label Phase II Study of the EORTC Melanoma Group (16032-18031)	1-gen-2009	Dreno, B; Mortier, L; Robert, C; Chiarion Sileni, V; Testorill, A; Maio, M; Awada, A; Lehmann, F; Kruit, W	-
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients	1-gen-2009	DI GIACOMO, ANNA MARIA; Danielli, R; Calabro, L; Bertocci, E; Nannicini, C; Miracco, C; Biagioli, M; Mazzei, Ma; Altomonte, M; Maio, M	-
P7 Treatment with lpllimumab brings an advantage with reference to long-term survival: reflection rate after 24-months of patients with advanced melanoma from 3 phase II studies with 10mg/kg lpillimumab	1-gen-2009	O'Day, Sj; Schadendorf, D; Weber, J; Lebbe, C; Maio, M; Pehamberger, H; Harmankaya, K; Siegel, J; Hoos, A; Humphrey, R; Wolchok, J	-
P10 lpillimumab in a dose of 10mg/kg improves in patients sith melanoma in stage M1c the disease progression independent of lactat-dehydrogenase (LDH) level	1-gen-2009	Smylie, M; Kaehler, Kc; Francis, S; Nyens, B; Maio, M; Minor, D; Verschraegen, C; Chin, K; Ibrahim, R; Hoos, A; Schadendorf, D	-
Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials	1-gen-2009	Maio, M; Lebbe, C; Sileni Chiarion, V; Siegel, J; Hoos, A; Humphrey, R; O'Day, S; Wolchok, J; Weber, J; Harmankaya, K	-
Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors	1-gen-2009	Schadendorf, D; Wolchok, J; Neyns, B; Lebbe, C; Harmankaya, K; Verschraegen, C; Chin, K; de Pril, V; Hoos, A; Maio, M	-
Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma	1-gen-2010	Wolchok, Jd; Weber, Js; Hamid, O; Lebbe, C; Maio, M; Schadendorf, D; de Pril, V; Ibrahim, R; Hoos, A; O'Day, Sj	-
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide	1-gen-2010	Coral, S; Sigalotti, L; Parisi, G; Colizzi, F; Fratta, E; Nicolay, Hjm; Taverna, P; Maio, M	-
Health-Care resource Utilization in advanced melanoma: an analysis from the MELODY observational study	1-gen-2010	Lorigan, P; Maio, M; Middleton, M; Testori, A; Bedane, C; van Baardewijk, M; Konto, C; Dueymes, A; Lebbe, C	-
Immunobiologic Activity of the Demethylating Dinucleotide SGI-110	1-gen-2010	Coral, S; Sigalotti, L; Fonsatti, E; Parisi, G; Colizzi, F; Nicolay, Hj; Taverna, P; Maio, M	-
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients	1-gen-2010	Danielli, R; Queirolo, P; Testori, A; Plummer, R; Sileni Chiarion, V; Altomonte, M; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M	-
Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients	1-gen-2011	Weide, B; Zelba, H; Derhovanessian, E; Pflugfelder, A; Schadendorf, D; de Vries, J; Maio, M; Garbe, C; Pawelec, G	-
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial	1-gen-2011	DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pittiglio, E; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Parmiani, G; Maio, M	-
Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma	1-gen-2011	Robert, C; Thomas, L; Garbe, C; Lebbe, C; Baurain, Jf; Testori, A; Maio, M; Chen, T; Hoos, A; Wolchok, J	-
Estratto della tesi di dottorato: “Il principio del vivente nelle anonime Questiones super librum de anima (ms. Siena, Bibl. Com. degli Intronati L.III.21, ff. 136ra-174ra”,	1-gen-2005	Bernardini, Paola	-
Guest Editorial “Secure lightweight crypto-hardware”	1-gen-2017	Acosta, A.; Addabbo, T.	-
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy	1-gen-2019	Bargagli, E; Bergantini, L; Cameli, P; D'Alessandro, M; Bini, L; Rottoli, P; Landi, C	-
Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: experience from Italian clinics participating in the European expanded access programme (EAP)	1-gen-2012	Maio, M; Chiarion Sileni, V; Pilla, L; Nicoletti, Svl; Di Guardo, L; Queirolo, P; De Galitiis, F; Mandala, M; Guida, M; Ascierto, Pa	-
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases	1-gen-2012	Maio, M; Testori, A; Ascierto, Pa; Ridolfi, R; Santinami, M; Pilla, L; Queirolo, P; Grosso, M; Simeone, E; Vittoria, S; Nicoletti, L; Rivoltini, L; Ferrucci, Pf; Parmiani, G; DI GIACOMO, ANNA MARIA	-
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma	1-gen-2012	Sigalotti, L; Fratta, E; Parisi, G; Covre, A; Sonego, P; Rizzo, A; Colizzi, F; Coral, S; Massarut, S; Maio, M	-

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 141 a 160 di 1.775

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext1241
reserved439
open79
internalNetwork13
partially open3